14:01 , Mar 25, 2019 |  BC Extra  |  Company News

Thermo Fisher buying gene therapy manufacturer Brammer Bio

Thermo Fisher will pay $1.7 billion to acquire gene and cell therapy contract development and manufacturing company Brammer Bio, giving it vector manufacturing sites in Massachusetts and Florida. Thermo Fisher Scientific Inc. (NYSE:TMO), which chiefly...
17:55 , Oct 26, 2018 |  BC Week In Review  |  Company News

NeoGenomics to acquire Genoptix

Genoptix was founded in 1999, went public in 2007 and in 2011 was acquired by Novartis AG (NYSE:NVS; SIX:NOVN). Ampersand Capital Partners and 1315 Capital acquired the company from Novartis in 2017. Genoptix Inc., Carlsbad,...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Genewiz completes venture financing

Genewiz Inc. , South Plainfield, N.J.   Business: Supply/Service, Genomics   Date completed: 2016-01-11   Type: Venture financing   Raised: Not disclosed   Investors: OrbiMed Advisors; Ampersand Capital; Prime Value Capital Management   Note: The...
07:00 , Jun 17, 2013 |  BioCentury  |  Finance

LP tracks

LP tracks Janine Guillot stepped down as chief operating investment officer at the California Public Employees' Retirement System (CalPERS), effective May 24. Carol Moody was named interim COIO by CalPERS. PE tracks Cecil Kost joined...
08:00 , Mar 4, 2013 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks Michael Heider joined Bank am Bellevue as head of research. Heider was co-head of equity research and a member of the executive committee at Helvea S.A. Banker tracks Hunt Henrie joined MedPanel LLC...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Financial News

ChanRx completes venture financing

ChanRx Corp. , Cleveland, Ohio   Business: Cardiovascular   Date completed: 11/21/11   Type: Venture financing   Raised: Not disclosed   Investors: Sante Ventures; Ampersand Ventures; company founders  ...
07:00 , Jun 14, 2010 |  BioCentury  |  Finance

Talecris takeout, again

Talecris takeout, again Investors in the October 2009 IPO by Talecris Biotherapeutics Inc. (NASDAQ:TLCR) will get their initial investment back in cash, plus a bit tacked on in shares, under a takeout bid from fellow...
07:00 , Oct 5, 2009 |  BioCentury  |  Finance

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
07:00 , Mar 16, 2009 |  BioCentury  |  Finance

Ebb & Flow

Companies from across the development spectrum closed private rounds last week, with the amounts raised largely illustrative of how far up or downstream each company finds itself. On one end was Victory Pharma , a...